In the present study, we measured hippocampal N-acetyl-l-aspartate (NAA), choline (CHO) and creatine (CRE) values in patients with panic disorder and healthy control subjects using in vivo1H MRS.
Methods
We scanned 20 patients meeting Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for panic disorder and 20 matched healthy controls with a 1.5 Tesla GE Signa Imaging System and measured of NAA, CHO, and CRE in hippocampal regions.
Results
When NAA, CHO and CRE values were compared between groups, statistically significant lower levels for all ones were detected for both sides.
Conclusion
Consequently, in the present study we found that NAA, CHO and CRE values of the patients with panic disorder were lower than those healthy controls. Future studies involving a large number of panic patients may shed further light on the generalizability of the current findings to persons with panic disorder.
Panic disorder, which is classified as an anxiety disorder in Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV), is a severe psychiatric disorder associated with significant impairment of the patients' quality of life as well as their social life function. Lifetime prevalence of panic disorder varies 1 to 3 percent of the general population. It is a chronic and often disabling anxiety disorder. Panic disorder has panic attacks in its clinical presentation.
Although important neurobiological investigations have been made, our knowledge on its pathophysiology has not been enough yet. On the other hand, there are very limited neuroimaging investigations in panic disorder. Most studies1-11 and Gorman's hypothesis12 suggest that the aberrancies in structure or function in prefrontal cortex, ACC, amygdala, hippocampus may be closely related to the pathophysiology of panic disorder.
As for the functional brain investigations in panic disorder, first of all, we should mention about proton magnetic resonance spectroscopy (1H MRS) which was also used in the present investigation. MRS is a safe and non-invasive means of measuring the brain chemistry and metabolism in vivo and has an increasing trend in the investigations of neuroimaging of psychiatric disorders. In MRS, following neurochemicals had been measured; N-acetyl-l-aspartate (NAA; a marker of neuronal viability), glutamate and glutamine, choline (CHO; a marker of cell membrane turnover), myo-inositol, and creatine (CRE; a marker of cellular energy). Because a reduction of brain NAA is considered to reveal a loss of neurons and axons and/or neural dysfunction, with its effect on the neuronal integrity and viability one can be speculate that its more sensitivity to neuronal loss than structural magnetic resonance imaging (MRI) findings.13 Although several studies in patients with panic disorder revealed inconsistent results, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis may play a role in panic disorder.14 Hippocampus, a glucocorticoid feedback area, is highly sensitive to endogenous glucocorticoid levels and so is an important region affected by stress modulation organized by the hypothalamo-pituitary-adrenal axis (HPA).15-17 On the other hand, Massana et al.18 performed a MRS study in patients with panic disorder and found that the concentration of creatine and phosphocreatine was significantly lower in the right medial temporal lobe region of panic disorder patients compared to healthy subjects while no significant differences between the two groups were observed in the medial prefrontal cortex. Moving from this point, as part of a larger effort to further characterize the role of the hippocampus in panic disorder which has been already emphasized,12 we performed a MRS investigation in which following neurochemicals had been measured; NAA (a marker of neuronal viability), CHO (a marker of cell membrane turnover), CRE (a marker of cellular energy) in hippocampus of the patients with panic disorder and hypothesized that hippocampal neurochemicals would change in this group of patients compared to healthy persons.
METHODS
Patients were selected among those with panic disorder according to DSM-IV belonging to our another unpublished study. Thus, 20 patients were invited to participate in the present study and seventeen accepted. The Structured Clinical Interview for the DSM-IV (SCID)19 and the Hamilton Depression Rating Scale (HDRS), which determines the severity of the depressive symptoms,20 and Panic Agoraphobia Scale (PAS)21 were used to assess participants. The patients were initially screened for potential inclusion in the present study before being further screened for inclusion in the MRS study. Healthy volunteers were recruited from the hospital staff. This study was carried out under guidelines of Helsinki Declaration. Written informed consent was obtained from all subjects.
The subjects were excluded if any of them have the presence of any current comorbid psychiatric disorder apart from depressive disorder, current medical problems, or alcohol/substance abuse within the 6 months preceding the study. Of the patients, two met criteria for major depressive disorder while following lifetime comorbidities were determined: social anxiety disorder (n=1), hypochondriasis (n=1), and obsessive compulsive disorder (n=1). Matched controls were selected among those who had no DSM-IV Axis I disorders in self or in a first-degree relative, as determined by the SCID non-patient version, no current medical problems, neurologic or psychiatric histories, and no use of psychoactive medication.
MRI procedure
Magnetic resonance imaging was conducted at the Firat University Hospital, Department of Radiology, Center of Neuroradiology at a 1.5-Tesla GE signa Excite high speed scanner (Milwakuee, USA). With the following parameters, MRI scans were obtained: repetition time (TR)=2000 ms, echo time (TE)=15.6 ms, field of view (FOV)=240 mm, flip angle=20°, bandwidth=20.8, slice thickness=2.4 mm, echo spacing=15.6 ms, 8 echoes, matrix size=240, and resolution=0.9375×0.9375×2.4 mm. In addition, hippocampus tracings were performed in according to with our another study,22 with the GE Volume Viewer voxtool 4.2 program and to with standard anatomic atlases.23,24 For MRS evaluations, the method administered by Bertolino et al.25 was used. Afterwards, NAA, CRE, and CHO levels were investigated. NAA, CHO, and CRE peaks were determined automatically for all voxels which were included within the hippocampus. Otherwise they were removed. Consequently, for only on voxels containing 1H spectra, final calculations were carried out. Position of hippocampal voxels and sample magnetic resonance spectrum are presented in Figure 1.
Statistical analysis
All analyses were conducted using the SPSS for Windows software, version 13.0 (SPSS Inc., Chicago, IL, USA). A two-tailed statistical significance level was set at p<0.05 for all analyses. The differences between patients and controls tested separately by a one-way analysis of variance (ANOVA), with hemisphere (left or right) as the within-group factor and diagnosis as the between-group factor were determined for metabolyte ratios. Categorical data were assessed by using chi-square test while group differences in demographic variables involving continuous data were computed using independent t-test. For correlations, Pearson's correlation test was used.
RESULTS
As presented in Table 1, there were no significant differences in demographic variables of age, gender composition, educational level, and handedness between the patients with panic disorder and comparison subjects. Furthermore, no structural abnormalities were noted qualitatively on the MRI scans of the patients or controls. It was also demonstrated the the results of hippocampus 1H MRS forthe patients and healthy volunteers.
When NAA values were compared between groups, statistically significant difference was detected for both sides (patients, mean±SD=430.00±252.62; controls, mean±SD=952.76±107.51; t=-7.85, p<0.001 for left side; patients, mean±SD=397.18±123.41; controls, mean±SD=832.82±124.14; t=-10.26, p<0.001 for right side). In regard to totally NAA, the difference was maintained (patients, mean±SD=827.17±330.92; controls, mean±SD=1785.59±144.03; t=-10.95, p<0.001). With respect to CHO levels, statistically significant difference was detected for both sides (patients, mean±SD=430.00±252.62; controls, mean±SD=952.76±107.51; t=-7.85, p<0.001 for left side; patients, mean±SD=397.18±123.41; controls, mean±SD=832.82±124.14; t=-10.26, p<0.001 for right side). The difference for total CHO was maintained (patients, mean±SD=827.17±330.92; controls, mean±SD=1785.59±144.03; t=-10.95, p<0.001). As for the CRE values, same diferences were detected. The mean CRE levels of the patient group was statistically significant lower compared to that of control ones (patients, mean±SD=430.00±252.62; controls, mean±SD=952.76±107.51; t=-7.85, p<0.001 for left side; patients, mean±SD=397.18±123.41; controls, mean±SD=832.82±124.14; t=-10.26, p<0.001 for right side). Likewise, total CRE was lower in the patients than control subjects (patients, mean±SD=827.17±330.92; controls, mean±SD=1785.59±144.03; t=-10.95, p<0.001). When general linear model was used, age and TBV corrected NAA levels were significantly lower in patients compared to controls, with a main effect of diagnosis (F=10.24, p=0.003) and without a main effect of age (F=1.43, p=0.24) and TBV (F=2.04, p=0.16). In addition, CHO values were significantly lower in the patients compared to controls, with a main effect of diagnosis (F=5.70, p=0.024) and without a main effect of age (F=0.14, p=0.71) and TBV (F=0.021, p=0.89). Likewise, CRE values were significantly lower in patients compared to controls, with a main effect of diagnosis (F=13.03, p=0.001) and without a main effect of age (F=0.39, p=0.54) and TBV (F=0.59, p=0.45). The mean hippocampus NAA/CRE ratio of the patients did not differ to that of control subjects (patients, mean±SD=1.34±0.35; controls, mean±SD=1.42±0.18; t=-0.81, p=0.42). Likewise, NAA/CHO ratio of the patients with panic disorder did not differ that of the control subjects, as determined by unpaired t test (patients, mean±SD=0.93±0.24; controls, mean±SD=1.04±0.10; t=-0.64, p=0.11). On the other hand, no significant difference was detected between groups in regard to CHO/CRE ratio (patients, mean±SD=1.46±0.27; controls, mean±SD=1.37±0.18; t=1.06, p=0.29). NAA, CHO, or CRE values were did not correlate with hippocampus volumes, HDRS or PAS scores.
DISCUSSION
In the present study, we found some important findings. When NAA, CHO and CRE values were compared between groups, statistically significant lower levels for all ones were detected for both sides. This change is independent of volumes because of the fact that there was no volume difference between groups for both sides and that no correlation was found between NAA, CHO, or CRE values and hippocampus volumes. At this point, we require to mention about our previous investigations in a variety of psychiatric disorders on NAA. In the other studies of ours, it was showed that NAA might also play an important role on the pathophyiology of bipolar disorder and obsessive compulsive disorder (OCD), and on the neuroprotective effect of quetiapine.26-28 These findings are very important since the role of NAA is established in neuronal integrity. Disablement in neuronal integrity may be associated with a neurodegenerative process and this may be related to the pathogenesis of panic disorder. Despite several investigations in patients with panic disorder revealed inconsistent results, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis may play a role in panic disorder.14 Hippocampus, a glucocorticoid feedback area, is highly sensitive to endogenous glucocorticoid levels and so is an important region affected by stress modulation organized by the hypothalamo-pituitary-adrenal axis (HPA).15-17 In this context, there may be an association between HPA dysregulation and hippocampus neurochemicals. There is only one study on hippocampal neurochemicals in the patients with panic disorder.28 In their study, Trzesniak et al.28 comprised 25 panic patients and 18 healthy control subjects and found that compared with controls, panic patients demonstrated significantly lower NAA/CRE in the left hippocampus. They suggested that left hippocampal NAA/CRE in panic disorder might be reflecting neuronal loss or neuronal metabolic dysfunction in that disorder, as discussed by us.
As for the CHO and CRE values, we found significantly reduced levels for both neurochemicals in the patients with panic disorder in contrast to the study performed by Trzesniak et al.29 who did not detected any CHO difference between panic patients and healthy control subjects. On the other hand, they found significant lower NAA/CRE ratio in the right hippocampus. We did not the exact reason between the findings of their study and ours. However, some confounding factors may contribute to this discrepancy. First of all, in their study, the mean age of the patients (39.2±9.9) is considerably higher than that of the present study (33.41±6.95). Secondly, in their study, sixteen of the patients were receiving pharmacological treatment at the time of MRI scanning. It was shown phosphotidylcholine breakdown to have an important role in signal transduction30 suggesting that reduced CHO concentrations in patients with panic disorder might contribute to the pathophysiology of the disorder by this way. Reduced CRE values were also reported by Massana et al.18 who found that the concentration of creatine and phosphocreatine was significantly lower in the right medial temporal lobe region of panic disorder patients compared to healthy subjects, without any significant differences for the medial prefrontal cortex and concluded that these results provided neurochemical evidence suggesting the involvement of the amygdalohippocampal region in the pathogenesis of panic disorder. Our same finding in the present study was important when we take into consideration that as implicated by Trzesniak et al.,29 CRE is thought to be relatively stable among individuals and in most brain areas; for this reason, it is often used as an internal reference. In the present study, absolute NAA, CHO, and CRE meaurements were discussed rather than metabolite ratios. The main reason why we done such a thing that NAA metabolite ratios must explain the alterations in the CRE reference peak that make out of vogue their usefulness as an internal reference for the other metabolite peaks.31,32
Several limitations exist with the present study. First of all, our sample size is small. This may limit the generalizability of our findings to all panic patients. Second, we only evaluated hippocampal region, however, some other important anatomic regions should be incuded in 1H MRS studies on panic disorder.
Consequently, in the present study we found that NAA, CHO and CRE values of the patients with panic disorder were lower than those healthy controls. Future studies involving a large number of panic patients may shed further light on the generalizability of the current findings to persons with panic disorder.
FontaineRBretonGDeryRFontaineSElieRTemporal lobe abnormalities in panic disorder: an MRI study1990273043102302439VythilingamMAndersonERGoddardAWoodsSWStaibLHCharneyDSTemporal lobe volume in panic disorder-- a quantitative magnetic resonance imaging study200099758210963983MassanaGSerra-GrabulosaJMSalgado-PinedaPGastoCJunqueCMassanaJParahippocampal gray matter density in panic disorder: a voxel-based morphometric study200316056656812611840MassanaGSerra-GrabulosaJMSalgado-PinedaPGastoCJunqueCMassanaJAmygdalar atrophy in panic disorder patients detected by volumetric magnetic resonance imaging200319809012781728UchidaRRDel-BenCMSantosACAraujoDCrippaJAGuimaraesFSDecreased left temporal lobe volume of panic patients measured by magnetic resonance imaging20033692592912845380YooHKKimMJKimSJSungYHSimMELeeYSPutaminal gray matter volume decrease in panic disorder: an optimized voxel-based morphometry study2005222089209416262646ProtopopescuXPanHTuescherOCloitreMGoldsteinMEngelienAIncreased brainstem volume in panic disorder: a voxel-based morphometric study20061736136316514359FischerHAnderssonJLFurmarkTFredriksonMBrain correlates of an unexpected panic attack: a human positron emission tomographic study19982511371409718993CoplanJDLydiardRBBrain circuits in panic disorder199844126412769861469PillaySSGruberSARogowskaJSimpsonNYurgelun-ToddDAfMRI of fearful facial affect recognition in panic disorder: the cingulate gyrus-amygdala connection20069417318116782207SchunckTErbGMathisAGillesCNamerIJHodeYFunctional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety2006311197120816600640GormanMKentJMSullivanGMCoplanJDNeuroanatomical hypothesis of panic disorder, revised200015749350510739407GuimaraesARSchwartzPPrakashMRCarrCABergerUVJenkinsBGQuantitative in vivo 1H nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain199569109511018848098AbelsonJLKhanSLiberzonIYoungEAHPA axis activity in patients with panic disorder: review and synthesis of four studies200724667616845643ShelineYIWangPWGadoMHCsernanskyJGVannierMWHippocampal atrophy in recurrent major depression199693390839138632988HoschlCHajekTHippocampal damage mediated by corticosteroids--a neuropsychiatric research challenge2001251Suppl 2II81II8811824844MizoguchiKIshigeAAburadaMTabiraTChronic stress attenuates glucocorticoid negative feedback: involvement of the prefrontal cortex and hippocampus200311988789712809708MassanaGGastóCJunquéCMercaderJMGómezBMassanaJReduced levels of creatine in the right medial temporal lobe region of panic disorder patients detected with (1)H magnetic resonance spectroscopy20021683684212169267CorapçıoğluAAydemirOYıldızM1999AnkaraHekimler Yayın BirliğiHamiltonMDevelopment of a rating scale for primary depressive illness196762782966080235BandelowBAssessing the efficacy of treatment for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale19951073817673659AtmacaMSirlierBYildirimHKayaliAHippocampus and amygdalar volumes in patients with somatization disorder2011351699170321651951DuvernoyHMCabanisEA1991New YorkSpringer-VerlagTalairachJTournouxP1998New YorkThieme Medical PublishersBertolinoAFryeMCallicottJHMattayVSRakowRShelton-RepellaJNeuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging20035390691312742678AtmacaMYildirimHOzdemirHPoyrazAKTezcanEOgurEHippocampal 1H MRS in first-episode bipolar I patients2006301235123916725248AtmacaMYildirimHOzdemirHOgurETezcanEHippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine20073712112917094813AtmacaMYildirimHOzdemirHKocMOzlerSTezcanENeurochemistry of the hippocampus in patients with obsessive-compulsive disorder20096348649019531109TrzesniakCUchidaRRAraújoDGuimarãesFSFreitas-FerrariMCFilhoAS(1) H magnetic resonance spectroscopy imaging of the hippocampus in patients with panic disorder201018226126520488674ExtonJHPhophatidylcholine breakdown and signal transduction1994121226428155724DeickenRFPeguesMPAnzaloneSFeiwellRSoherBLower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder200316087388212727690RossBMichaelisTClinical applications of magnetic resonance spectroscopy1994101912477873353
Position of hippocampal voxels and sample magnetic resonance spectrum.
Demographic, clinical, volumetrik and spectroscopic and 1H MRS data of the patients and controls
No significant differences exist between groups in age, handedness, education, and gender composition. *p<0.001. F: female, M: Male, HDRS: Hamilton Depression Rating Scale, NAA: N-acetyl aspartate, CHO: choline, CRE: creatine, 1H MRS: proton magnetic resonance specroscopy